Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging.Objectives
 The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).  The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.


 This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020.  The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson.  The collected data included the patients' characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements.


 Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639).  Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%.  There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563).  However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001).


 Conclusion
 Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI.  However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.
C
The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).  The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.


 This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020.  Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. 
SPECT
Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging.Objectives
 The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.


 The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson.  Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639).  There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563).  However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001).


 Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI.  However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.
regadenoson
Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging.Objectives
 The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.


 The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson.  There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563).  However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001).


 Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. 
dipyridamole